Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease

Modern Pathology

Volumn 26, Issue 2, 2013, Pages 204-212

  Boiocchi, Leonardo ^a,c   Espinal Witter, Rosanny ^a   Geyer, Julia Turbiner ^a   Steinhilber, Julia ^b   Bonzheim, Irina ^b   Knowles, Daniel M ^a   Fend, Falko ^b   Orazi, Attilio ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

accelerated phase; chronic myelomonocytic leukemia; disease progression; monocytosis; primary myelofibrosis; prognosis

Indexed keywords

HEMOGLOBIN; JANUS KINASE; K RAS PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CODON; DISEASE COURSE; FEMALE; GENE MUTATION; HUMAN; LEUKOCYTE; MALE; MONOCYTOSIS; MYELOID METAPLASIA; MYELOMONOCYTIC LEUKEMIA; PRIORITY JOURNAL; THROMBOCYTE COUNT;

EID: 84873407303     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.165     Document Type: Article

References (31)

1. Thiele J, Kvasnicka HM, Tefferi A, et al. Primary myelofibrosis, In: Swerdlow SH, Campo E, Harris NL, et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon; 2008, pp 44-47.
2. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113:2895-2901.
3. Orazi A, Chiu R, O'Malley DP, et al. Chronic myelo-monocytic leukemia: The role of bone marrow biopsy immunohistology. Mod Pathol 2006;19:1536-1545.
4. Orazi A, Germing U. The myelodysplastic/myelopro-liferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 2008;22:1308-1319.
5. Orazi A, Bennett JM, Germing U, et al. Chronic myelomonocytic leukaemia, In: Swerdlow SH, Campo E, Harris NL, et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon; 2008, pp 76-79.
6. Wang SA, Galili N, Cerny J, et al. Chronic myelomo-nocytic leukemia evolving from preexisting myelodys-plasia shares many features with de novo disease. Am J Clin Pathol 2006;126:789-797.
7. Takasaki Y, Iwanaga M, Tsukasaki K, et al. Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res 2007;31:751-757.
8. Chen MH, Chang PM, Chen PM, et al. Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer. J Cancer Res Clin Oncol 2009;135:1783-1790.
9. Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 2007;31: 1503-1509.
10. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders-current diagnostic approach. Semin Hematol 2005;42:184-195.
11. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-1132.
12. Shaffer LG, Slovak ML, Campbell LJ. (eds)ISCN (2009): an International System for Human Cytogenetic No-menclatureKarger: Basel, 2009.
13. Chen Q, Lu P, Jones AV, et al. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. J Mol Diagn 2007;9:272-276.
14. Dabritz J, Hanfler J, Preston R, et al. Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Br J Cancer 2005;92:405-412.
15. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008;112:2726-2732.
16. Morel P, Duhamel A, Hivert B, et al. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood 2010;115:4350-4355.
17. Cervantes F, Pereira A. Prognostication in primary myelofibrosis. Curr Hematol Malig Rep 2012;7:43-49.
18. Qubaja M, Marmey B, Le Tourneau A, et al. The detection of CD14 and CD16 in paraffin-embedded bone marrow biopsies is useful for the diagnosis of chronic myelomonocytic leukemia. Virchows Arch 2009;454:411-419.
19. Dunphy CH. Comparative analysis of detecting mono-cytic cells and their aberrancy. Appl Immunohisto-chem Mol Morphol 2011;19:336-340.
20. Rollins-Raval MA, Roth CG. The value of immunohis-tochemistry for CD14, CD123, CD33, myeloperoxidase and CD68R in the diagnosis of acute and chronic myelomonocytic leukaemias. Histopathology 2012;60: 933-942.
21. Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol 2009;82:329-338.
22. Ricci C, Fermo E, Corti S, et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res 2010;16:2246-2256.
23. Pich A, Riera L, Sismondi F, et al. JAK2V617F activating mutation is associated with the myeloproli-ferative type of chronic myelomonocytic leukaemia. J Clin Pathol 2009;62:798-801.
24. Beer PA, Delhommeau F, LeCouedic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010;115:2891-2900.
25. Hussein K, Bock O, Seegers A, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007; 109:4106-4107.
26. Hussein K, Bock O, Theophile K, et al. Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation. Blood 2009;113:1391-1392.
27. Schaub FX, Jager R, Looser R, et al. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood 2009;113:2022-2027.
28. Sokol L, Caceres G, Rocha K, et al. JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. Leuk Res 2010;34:821-823.
29. Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010;115:2003-2007.
30. Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010;116:3923-3932.
31. Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010;28:3858-3865.